Gilotrif (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022

Date: July 30, 2013
Pages: 71
Price:
US$ 3,495.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: G5F8BEDD6C3EN
Leaflet:

Download PDF Leaflet

Gilotrif (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022
Gilotrif (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022

Summary

Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men and women. Historically, the treatment paradigm has centered around chemotherapy. However, the launch of targeted therapies for patients with specific biomarkers has begun to fragment the NSCLC treatment landscape into smaller niche patient populations. Over the forecast period, this trend will continue with the launch of multiple new drugs in several new drug classes to address the high unmet need among NSCLC patients, and provide new treatment options for previously underserved populations. Launch of premium-priced drug candidates combined with increasing incident cases of the disease will be major drivers of growth in the major markets.
Gilotrif is an irreversible inhibitor of the ErbB family of receptors, which include EGFR and HER2, and it has TKI activity against the wild-type as well as the mutant EGFR receptor. This distinguishes it from Tarceva and Iressa, which are reversible TKIs that only target the mutant receptor. Boehringer Ingelheim received FDA marketing approval for Gilotrif in July 2013 for the first-line treatment of EGFR-mutant NSCLC patients.

Scope
  • Overview of NSCLC, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Gilotrif including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Gilotrif for the top nine countries from 2012 to 2022.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, India and China.
Reasons to buy
  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for NSCLC
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Gilotrif performance
  • Obtain sales forecast for Gilotrif from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, India and China)
1 TABLE OF CONTENTS

1.1 List of Tables
1.2 List of Figures

2 INTRODUCTION

2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports

3 DISEASE OVERVIEW

3.1 Etiology and Pathophysiology
  3.1.1 Etiology
  3.1.2 Pathophysiology and Histology
  3.1.3 NSCLC Biomarkers
  3.1.4 Quality of Life
3.2 Symptoms

4 DISEASE MANAGEMENT

4.1 Treatment Overview
  4.1.1 Diagnosis
  4.1.2 Clinical Staging
  4.1.3 Screening and Early Detection
  4.1.4 Localized Procedures and Therapies
  4.1.5 Systemic Chemotherapy
  4.1.6 Targeted Therapy

5 COMPETITIVE ASSESSMENT

5.1 Overview
5.2 Strategic Competitor Assessment

6 OPPORTUNITY AND UNMET NEED

6.1 Overview
6.2 Improved Overall Survival and Less Toxicity
6.3 Treatments for Patients with Acquired TKI Resistance
6.4 Better Treatment Options for Squamous Patients
6.5 Preventing Relapse or Recurrence
6.6 More Efficacious Second-Line Therapies
6.7 Increased Availability of Mutation Testing
6.8 More Cost-Effective Therapies
6.9 Unmet Needs Gap Analysis

7 PIPELINE ASSESSMENT

7.1 Overview
7.2 Promising Drugs in Clinical Development

8 GILOTRIF (AFATINIB)

8.1 Overview
8.2 Efficacy
8.3 Safety
8.4 Dosing and Formulation
8.5 Potential Clinical Positioning
8.6 Potential Commercial Positioning
8.7 Pricing and Reimbursement
8.8 SWOT Analysis
8.9 Forecast

9 APPENDIX

9.1 Bibliography
9.2 Abbreviations
9.3 Methodology
9.4 Forecasting Methodology
  9.4.1 Number of NSCLC Patients Currently Seeking Treatment
  9.4.2 Percent Drug-treated Patients
  9.4.3 General Pricing Assumptions
  9.4.4 Individual Drug Assumptions
  9.4.5 Generic Erosion
  9.4.6 Pricing of Pipeline Agents
9.5 Physicians and Specialists Included in This Study
9.6 Survey of Prescribing Physicians
9.7 About the Authors
  9.7.1 Author
  9.7.2 Epidemiologist
  9.7.3 Global Head of Healthcare
9.8 About GlobalData
9.9 Disclaimer

LIST OF TABLES

Table 1: Symptoms of Disease NSCLC
Table 2: Treatment Guidelines for NSCLC
Table 3: Stage Definitions for NSCLC
Table 4: Treatment Overview by Stage of Diagnosis for NSCLC
Table 5: Leading Treatments for NSCLC
Table 6: Overall Unmet Needs – Current Level of Attainment
Table 7: Clinical Unmet Needs – Gap Analysis, 2013
Table 8: Non-Small Cell Lung Cancer – Phase I-II Pipeline, 2013
Table 9: NSCLC – Phase III Pipeline, 2013
Table 10: NSCLC – Advantages and Disadvantages of Therapeutic Classes
Table 11: Product Profile – Gilotrif (afatinib)
Table 12: Gilotrif SWOT Analysis, 2013
Table 13: Global Sales Forecasts ($m) for Gilotrif, 2012-2022
Table 14: Five Year Prevalence
Table 15: Physicians Surveyed by Country

LIST OF FIGURES

Figure 1: Competitive Assessment of Late-Stage Pipeline Agents in NSCLC, 2012–2022

Ask Your Question

Gilotrif (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: